ArticleTissue engineering and regenerative medicine2025
Angiogenic Ability of Extracellular Vesicles Derived from Angio-miRNA-Modified Mesenchymal Stromal Cells.
Article in Tissue engineering and regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioengineered Cellular and Acellular Therapies for Ischemic Heart Disease in Clinically Relevant Models.Bioengineering (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRegenerative therapy using extracellular vesicles (EVs) is a promising approach for the supportive treatment of chronic limb-threatening ischaemia. Herein, we examined the angiogenic potential of EVs derived from genetically modified mesenchymal stromal cells (MSCs), focusing on the angio-micro RNAs (miRNAs) in EVs.
methodsBone marrow-derived MSCs (BM-MSCs) were transfected with lentiviral vectors containing specific angio-miRNAs (miRNA-126, -135b, or -210), and miRNA overexpression was confirmed using quantitative polymerase chain reaction (qPCR). EVs were isolated from the BM-MSC culture medium and characterised using fluorometry, nanoparticle tracking analysis, and ExoScreen assays. In vitro, human umbilical vein endothelial cells (HUVECs) were used to evaluate the angiogenic potential of the EVs. In vivo, EVs were injected into the ischaemic hindlimb muscles of mice, and limb ischaemia severity, blood perfusion, and histological analysis of muscle tissue were performed.
resultsqPCR analysis confirmed the overexpression of angio-miRNAs in MSCs transfected with lentiviral vectors. Isolated EVs expressed CD63 and had consistent protein-to-particle ratios. Tube formation was significantly enhanced when HUVECs were cultured with EV126, EV135b, or their combination (EV126 + EV135b) (p < 0.05), compared to BM-MSC co-culture. In vivo, only the double and triple EV groups significantly improved limb perfusion compared to the EVcontrol (p < 0.05); single EVs showed no significant difference. Histological analysis showed increased capillary density in ischaemic muscles following injection of combined EVs.
conclusionEVs derived from genetically modified MSCs promoted angiogenesis both in vitro and in vivo, with a combination of modified EVs demonstrating significantly superior therapeutic effects than single or native EVs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.